Xizhe Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xizhe Wang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Anna Mathioudaki
Molecular Systems Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
1 shared publication Aryan Kamal
Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
1 shared publication- Caroline Pabst
Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
1 shared publication - Carsten Müller-Tidow
University Hospital Heidelberg, Heidelberg, Germany
1 shared publication David Sedloev
Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
1 shared publication- Judith Barbara Zaugg
Department of Biomedicine, University of Basel, Basel, Switzerland
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 28 March 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (13) , 1269-1281
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature
Acute myeloid leukemia (AML) is a hematologic malignancy for which allogeneic hematopoietic cell transplantation (allo-HCT) often remains the only curative therapeutic approach. However, incapability of T cells to recognize and eliminate residual leukemia stem cells might lead to an insufficient graft-versus-leukemia (GVL) effect and relapse. Here, we performed single-cell RNA-sequencing (scRNA-seq) on bone marrow (BM) T lymphocytes and CD34+ cells of 6 patients with AML 100 days after allo-HCT to identify T-cell signatures associated with either imminent relapse (REL) or durable complete remission (CR). We observed a higher frequency of cytotoxic CD8+ effector and gamma delta (γδ) T cells in CR vs REL samples. Pseudotime and gene regulatory network analyses revealed that CR CD8+ T cells were more advanced in maturation and had a stronger cytotoxicity signature, whereas REL samples were characterized by inflammatory tumor necrosis factor/NF-κB signaling and an immunosuppressive milieu. We identified ADGRG1/GPR56 as a surface marker enriched in CR CD8+ T cells and confirmed in a CD33-directed chimeric antigen receptor T cell/AML coculture model that GPR56 becomes upregulated on T cells upon antigen encounter and elimination of AML cells. We show that GPR56 continuously increases at the protein level on CD8+ T cells after allo-HCT and confirm faster interferon gamma (IFN-γ) secretion upon re-exposure to matched, but not unmatched, recipient AML cells in the GPR56+ vs GPR56– CD8+ T-cell fraction. Together, our data provide a single-cell reference map of BM–derived T cells after allo-HCT and propose GPR56 expression dynamics as a surrogate for antigen encounter after allo-HCT.
- 28 March 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (13) , 1269-1281
Top Cited PapersOpen AccessThe remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature
Acute myeloid leukemia (AML) is a hematologic malignancy for which allogeneic hematopoietic cell transplantation (allo-HCT) often remains the only curative therapeutic approach. However, incapability of T cells to recognize and eliminate residual leukemia stem cells might lead to an insufficient graft-versus-leukemia (GVL) effect and relapse. Here, we performed single-cell RNA-sequencing (scRNA-seq) on bone marrow (BM) T lymphocytes and CD34+ cells of 6 patients with AML 100 days after allo-HCT to identify T-cell signatures associated with either imminent relapse (REL) or durable complete remission (CR). We observed a higher frequency of cytotoxic CD8+ effector and gamma delta (γδ) T cells in CR vs REL samples. Pseudotime and gene regulatory network analyses revealed that CR CD8+ T cells were more advanced in maturation and had a stronger cytotoxicity signature, whereas REL samples were characterized by inflammatory tumor necrosis factor/NF-κB signaling and an immunosuppressive milieu. We identified ADGRG1/GPR56 as a surface marker enriched in CR CD8+ T cells and confirmed in a CD33-directed chimeric antigen receptor T cell/AML coculture model that GPR56 becomes upregulated on T cells upon antigen encounter and elimination of AML cells. We show that GPR56 continuously increases at the protein level on CD8+ T cells after allo-HCT and confirm faster interferon gamma (IFN-γ) secretion upon re-exposure to matched, but not unmatched, recipient AML cells in the GPR56+ vs GPR56– CD8+ T-cell fraction. Together, our data provide a single-cell reference map of BM–derived T cells after allo-HCT and propose GPR56 expression dynamics as a surrogate for antigen encounter after allo-HCT.